Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Heterozygous Familial Hypercholesterolemia (ODYSSEY FH II)
NCT01709500Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2012
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Alirocumab with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in Calculated LDL-C at Week 24. Started Dec 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01709500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709500.